Bayosthiti AI

What Bayosthiti AI does

Bayosthiti AI is an India-headquartered molecular diagnostics company and Indian subsidiary of Biostate AI, operating a C-CAMP-based laboratory in Bengaluru with 51-100 employees. The company combines proprietary wet-lab chemistry — patented BIRT (Barcode-Integrated Reverse Transcription) for RNA sequencing and DIMPLE for massively multiplexed qPCR — with internally developed AI models to deliver transcriptomic profiling, infectious disease detection, and prognostic analytics to hospitals, clinical researchers, pharmaceutical companies, and individual consumers.

The product portfolio spans a sample-to-insight stack: low-input RNA sequencing services (as little as 10ng input, up to 30,000 genes per sample), targeted NGS panels detecting 220+ pathogens, NIPT via both ddPCR and NGS, multiplex qPCR assays with up to 1,000 targets per tube, and dedicated point-of-care instruments (Bayosthiti Flash and GenPlex). On top of the wet-lab layer, the company runs a suite of AI products: Prognosis AI plus Omics Web Co-Pilot for outcome prediction and natural language bioinformatics; Bayosthiti Pragyan as a clinician-facing copilot; Bayosthiti Ayu as a consumer health app; K-Dense as an autonomous research scientist platform; and a roadmap "Lifecycle Twin" product for longitudinal health modeling. Predictive capabilities have been clinically validated in an AML relapse detection setting.

The company monetizes through a mixed revenue model including professional sequencing services, instrument and kit sales (Flash, GenPlex, Nimble, Pro, Evo), a Prognosis AI subscription platform, and bespoke qPCR development. Pricing is positioned 2-3x below conventional RNA sequencing alternatives, with infectious disease multiplex panels starting at less than ₹1,500 and tNGS panels starting below ₹5,000. Distribution combines direct enterprise field sales with lab-based services and an early-stage US market presence serving 150+ clients across 80+ completed pilot projects. The Narayana Health partnership (announced October 2025) anchors a 12,000-patient cardiovascular AI dataset targeting India's 65 million CAD-affected population.

Name

Bayosthiti AI

Legal name

Bayosthiti AI

Website

https://bayosthiti.ai

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

51–100 employees

Short description

Bayosthiti AI is an India-based molecular diagnostics company that combines patented BIRT RNA sequencing and DIMPLE qPCR multiplexing technologies with predictive AI platforms to serve hospitals, clinical researchers, pharmaceutical companies, and consumers across infectious disease, oncology, and cardiology.

Ownership category

akta.pro rank

Headquarters

HQ city

Bengaluru

HQ country

India

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. RNA Sequencing Services: RNA sequencing services using proprietary BIRT technology for transcriptome analysis. Services include pilot projects, cancer diagnostics, and cardiovascular disease testing. Turnaround time of 2-3 weeks.
2. Molecular Diagnostic Assays: NIPT (Non-Invasive Prenatal Testing) via ddPCR and NGS platforms, qPCR infectious disease testing, and targeted NGS panels for comprehensive disease detection.
3. Prognosis AI Platform Subscription: AI-powered disease prediction and bioinformatics analysis platform offered as web-based co-pilot for clinicians and researchers, with early adopter access program.
4. Point-of-Care Testing Instruments: Sale of proprietary instruments (Bayosthiti Flash, GenPlex, Nimble, Pro, Evo) along with testing kits for in-house laboratory testing.
5. Bespoke qPCR Kit Sales: Custom-designed qPCR kits for regional diseases and specific pathogen panels, available for purchase and in-house testing.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Core offering

Bayosthiti AI is an AI-first molecular diagnostics company that delivers RNA sequencing services, proprietary diagnostic assays (NIPT, infectious disease qPCR, targeted NGS panels), point-of-care instruments, and AI-powered copilots (Prognosis AI, K-Dense, Pragyan, Ayu) for clinical and research workflows in genomics and pathology. Its offering combines patented wet-lab chemistry (BIRT and DIMPLE) with generative AI models trained on India-specific molecular data to enable affordable, early-disease detection across maternal health, infectious disease, oncology, and cardiology.

Product overview

Bayosthiti AI is India's first comprehensive molecular profiling and diagnostics company operating as Biostate AI's Indian subsidiary. The company offers an integrated portfolio of proprietary molecular diagnostics products and AI platforms organized around its patented BIRT (Barcode-Integrated Reverse Transcription) and DIMPLE technologies. The core RNA sequencing services power a suite of diagnostic products including NIPT (ddPCR and NGS-based), infectious disease testing via Massively Multiplexed qPCR (up to 1000 targets) and Targeted NGS panels (>220 pathogens), and point-of-care assays with dedicated instruments (GenPlex, Flash). This is complemented by AI-powered offerings: Prognosis AI + Omics Web Co-Pilot for predictive analytics and natural language bioinformatics querying, Bayosthiti Ayu and Pragyan consumer/professional applications, K-Dense autonomous research platform, and the planned Lifecycle Twin. The product ecosystem integrates end-to-end from sample-to-insight and symptom-to-solution across mother-child health, infectious diseases, oncology, and cardiology.

Differentiator

Problem solved

Functional benefit

Brands

• Bayosthiti Ayu: Personal health AI co-pilot for patients - helps understand lab reports, track symptoms, and take control of health narrative.
• Bayosthiti Pragyan
• K-Dense
• Prognosis AI + Omics Web Co-Pilot

Products and services

• RNA Sequencing Services RNA sequencing services using proprietary BIRT technology, delivering robust transcriptome coverage (up to 30,000 genes per sample) at 2-3x lower cost than conventional methods with 2-3 week turnaround. Offered to academic, clinical research, and pharmaceutical customers.
• Highly Multiplexed PCR and Targeted NGS (tNGS) Panels Comprehensive infectious disease and drug resistance testing panels using targeted NGS, detecting over 220 pathogens and 37 resistance genes with 24-30 hour turnaround. Priced starting at less than ₹5000 per panel.
• Non-Invasive Prenatal Testing (NIPT) - ddPCR Non-invasive prenatal screening test using ddPCR technology for accurate fetal aneuploidy detection, targeted at maternal and infant health providers.
• Non-Invasive Prenatal Testing (NIPT) - NGS NGS-based non-invasive prenatal screening test for fetal aneuploidy detection, offered alongside the ddPCR-based NIPT option.
• Massively Multiplexed qPCR for Infectious Disease Testing Advanced infectious disease testing using proprietary DIMPLE technology to detect up to 1000 DNA/RNA targets in a single qPCR tube, with results in 2-3 hours and pricing starting at less than ₹1500.
• Point-of-Care Surveillance and Testing Assays Rapid qPCR and genotyping assays for point-of-care pathogen detection including respiratory panels (28 pathogens), gastrointestinal panels (27 pathogens), MTB mutation detection, and Brucella genotyping.
• Bayosthiti Flash qPCR Instrument User-friendly high-speed qPCR instrument designed for rapid point-of-care testing, delivering results in 60 minutes. Sold with comprehensive testing kits for in-house laboratory use.
• Bayosthiti GenPlex Genotyping Instrument
• Prognosis AI + Omics Web Co-Pilot Platform Two-stage AI platform combining biological signal extraction from RNA-seq and omics data with predictive modeling to predict disease outcomes, relapse probabilities, and treatment trajectories across oncology, cardiology, and autoimmune diseases. Includes natural language query capability for RNA data analysis. Offered via subscription with an early adopter program.
• Bayosthiti Ayu Consumer Health App Personal health AI co-pilot application for individual patients, helping users understand lab reports, track symptoms, and manage their personal health narrative through AI-powered insights.
• Bayosthiti Pragyan Clinician Co-Pilot AI co-pilot application for clinicians and researchers providing differential diagnosis support, deep molecular insights, and patient stratification tools as part of the 'Sample to Insight' workflow.
• K-Dense Autonomous AI Scientist Platform Autonomous AI scientist platform that conducts complete scientific research from hypothesis to publication with minimal human intervention, described as going from question to analysis to report.

Quantifiable outcome

• 2-3x lower cost than conventional RNA sequencing
• +6 more outcomes

Named customers2 records

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature6 records

Partnerships

One partnership is on record.

• Narayana HealthflagshipStrategic or Co-development Partner · 29 October 2025Bayosthiti AI partnered with Narayana Health to develop AI models that predict cardiovascular disease specifically for Indian populations. The collaboration analyzes molecular data from blood samples using RNA sequencing to identify disease patterns before traditional methods. The study aims to improve early detection of coronary artery disease, which affects 65 million Indians, by creating the world's largest India-specific cardiac AI dataset.

Scale indicators12 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• QIAGEN: Leading molecular diagnostics and sample-preparation company with broad PCR/NGS-based IVD assays, comparable to Bayosthiti's tNGS infectious disease and NIPT menu.
• bioMérieux (BioFire): Incumbent in syndromic infectious disease molecular diagnostics via the BioFire FilmArray panels, which Bayosthiti explicitly benchmarks its DIMPLE-based qPCR panels against.
• Thermo Fisher Scientific: Diversified life sciences and clinical diagnostics giant with qPCR instruments (QuantStudio), NGS panels, and clinical sequencing services that compete head-on with Bayosthiti's instruments, kits, and RNA-seq service offering.
• Bio-Rad Laboratories: Global life science and clinical diagnostics incumbent with a large qPCR, droplet digital PCR, and infectious disease testing portfolio that overlaps directly with Bayosthiti's DIMPLE-based qPCR and ddPCR NIPT offerings.

Direct peers

• MedGenome: India- and US-based genomics diagnostics company providing NGS-based tests for reproductive health, oncology, and rare disease — a direct regional competitor in NIPT and molecular diagnostics.
• Strand Life Sciences: India-based bioinformatics and molecular diagnostics company offering NGS-based cancer and rare disease panels and clinical genomics services, making it one of the closest domestic peers to Bayosthiti.
• Tempus AI: AI-native precision medicine company combining multi-omics sequencing with proprietary AI models for clinical decision support — closely aligned with Bayosthiti's RNA-seq-plus-AI thesis, especially in oncology.
• Natera: Molecular diagnostics company focused on NIPT, oncology recurrence monitoring, and organ transplant rejection testing — directly comparable to Bayosthiti's NIPT (ddPCR/NGS) and Prognosis AI cancer relapse prediction products.

Emerging players

• 10x Genomics: Provider of single-cell and spatial transcriptomics platforms, partially comparable to Bayosthiti's BIRT-based comprehensive transcriptome work in oncology and rare disease research.
• Personalis: Genomics and AI-driven cancer diagnostics company with a tumor-informed MRD assay and immuno-omics profiling, comparable to Bayosthiti's Prognosis AI relapse-prediction positioning in oncology.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/biostate-ai

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bayosthiti AI